Taha

Cumulus Media and YAP Media Form Partnership for Podcasts

Retrieved on: 
Thursday, September 22, 2022

NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Cumulus Media (NASDAQ: CMLS) today announced a partnership with YAP Media to monetize, market, and distribute all their existing and forthcoming podcasts.

Key Points: 
  • NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Cumulus Media (NASDAQ: CMLS) today announced a partnership with YAP Media to monetize, market, and distribute all their existing and forthcoming podcasts.
  • Joining the Cumulus Podcast Network is YAP Medias flagship podcast, Young and Profiting, hosted by YAP Media founder and CEO Hala Taha, who interviews the brightest minds in the world to unpack their wisdom into actionable advice.
  • Hala Taha is the host of the top-ranked Young and Profiting podcast and the CEO and founder of YAP Media, an award-winning social media and podcast marketing agency.
  • Cumulus Media is the only audio media company to provide marketers with local and national advertising performance guarantees.

BioVaxys Expands Cancer Vaccine Platform

Retrieved on: 
Wednesday, March 30, 2022

The BioVaxys vaccine platform is based on the established immunological concept that modifying surface proteins---whether they are viral or tumor---with haptens makes them more visible to the immune system. This process of haptenization "teaches" a patient's immune system to recognize and make target proteins more "visible" as foreign, thereby stimulating a T-cell mediated immune response.   BioVaxys' cancer vaccines are created by extracting a patient's own (i.e., autologous) cancer cells, chemically linking with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic.

Key Points: 
  • VANCOUVER, BC, March 30, 2022 /PRNewswire/ --BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today the expansion of its cancer vaccine platform with BVX-0922, its autologous haptenized tumor vaccine for colorectal cancer ("CRC").
  • The BioVaxys vaccine platform is based on the established immunological concept that modifying surface proteins---whether they are viral or tumor---with haptens makes them more visible to the immune system.
  • BioVaxys has a significant advantage over many other companies looking at cancer therapies in that it already has extensive promising clinical data for its cancer vaccines.
  • Finally, preliminary studies of a first generation, autologous, single-hapten vaccine have been performed in kidney cancer, non-small cell lung cancer, breast cancer, and acute myelogenous leukemia.

BioVaxys Expands Cancer Vaccine Platform

Retrieved on: 
Wednesday, March 30, 2022

The BioVaxys vaccine platform is based on the established immunological concept that modifying surface proteins---whether they are viral or tumor---with haptens makes them more visible to the immune system. This process of haptenization "teaches" a patient's immune system to recognize and make target proteins more "visible" as foreign, thereby stimulating a T-cell mediated immune response.   BioVaxys' cancer vaccines are created by extracting a patient's own (i.e., autologous) cancer cells, chemically linking with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic.

Key Points: 
  • VANCOUVER, BC, March 30, 2022 /PRNewswire/ --BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today the expansion of its cancer vaccine platform with BVX-0922, its autologous haptenized tumor vaccine for colorectal cancer ("CRC").
  • The BioVaxys vaccine platform is based on the established immunological concept that modifying surface proteins---whether they are viral or tumor---with haptens makes them more visible to the immune system.
  • BioVaxys has a significant advantage over many other companies looking at cancer therapies in that it already has extensive promising clinical data for its cancer vaccines.
  • Finally, preliminary studies of a first generation, autologous, single-hapten vaccine have been performed in kidney cancer, non-small cell lung cancer, breast cancer, and acute myelogenous leukemia.